An observational study in Death, sponsored by Paris Translational Research Center for Organ Transplantation. Enrolling by invitation at 11 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Paris Translational Research Center for Organ Transplantation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Death with a site in France — 14 open to participants now, 15 under way, 3 of them phase 3. Death · France.
Among the 51 studies in Death with a site in France, this one is the 3rd largest by planned enrollment of the 37 observational ones that give a count, is one of 2 that started in 2004, is one of 38 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 42nd registered.
457 studies on the registry are indexed under Death; 85 are open to participants now.
Browse Death studies →14 of the 51 studies in Death with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 0 days–3 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 13,000 is above the median of 400 across 236 observational studies indexed under Death.
Median enrollment 242 across the 13 interventional studies, 354 across the 37 observational. Of the 28 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 51 have an industry lead sponsor. The 10 most frequent:
Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.
Paris Translational Research Center for Organ Transplantation has 1 study filed under Death — fewer than ten, so there is no comparison to draw.
6 of the studies in Death with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06263816Phase 3University Hospital, ToursEffect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial | 2027-07-17 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
| NCT07895940University Hospital, Strasbourg, FrancePrehospital Care of End-of-Life Patients by the Strasbourg Mobile Emergency and Resuscitation Service: A Qualitative Study of Healthcare Professionals' Experiences and Use of a Comfort Care Booklet | 2027-01-06 |
| NCT07257861Centre Hospitalier Régional d'OrléansInterest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life | 2027-02 |
| NCT07273643University Hospital, MontpellierCharacterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality | 2027-10-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Death with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Accurately predicting kidney recipient risk of death has a crucial interest because of the organ shortage, the need to optimize allograft allocation by identifying high-risk patients who may not benefit from a transplant and improve the clinical decision-making after transplant to ensure that each patient survives as long as possible.
However, according to a literature review the investigators performed, studies attempting to develop a kidney recipient death prediction model suffer from many shortcomings, including the lack of key risk factors, use of biased registry data, small sample size, lack of external validation in different countries and subpopulations, and short follow-up.
The present study thus aimed to address these limitations and develop a robust, generalizable kidney recipient death prediction model.
The number of individuals suffering from end-stage chronic renal disease (ESRD) worldwide has increased over time, exceeding seven million of patients in 2020. For individuals with ESRD, kidney transplantation is the best treatment in terms of patient survival, quality of life and from a cost-effective standpoint, as compared with dialysis, even in comorbid or elderly populations.
Although the number of kidney transplantations performed each year has increased as well, it follows a lower pace than the increase of individuals on the waiting-list, resulting in an organ shortage. There is therefore a need to optimize allograft allocation by identifying the high-risk patients who may not benefit from a transplant and improve the clinical decision-making after transplant to ensure that each patient survives as long as possible.
In this context, a kidney recipient death prediction model may improve transplant clinical practice, allowing for the ability to evaluate the individual risk of post transplant mortality, already before undergoing transplantation, thereby guiding decision making. However, developing such a model is a very difficult task, as death after kidney transplantation depends on many parameters, such as donor age, history or cause of death, imaging parameters, patients' past medical history (e.g. diabetes, dialysis duration, hypertension), patients' biological parameters, as well as the function of the allograft, which depends on patients' immunological factors, or allograft related parameters such as HLA mismatches or cold ischemia time.
The goal of the present study was therefore to identify the determinants of death after kidney transplantation, and to develop and validate a prediction model that would help optimize allograft allocation and post-transplant patient management, using a large, international, highly phenotyped cohort of kidney recipients with extensive data collection and long-term follow-up.
Adult, de novo, kidney recipients who received only a kidney transplant
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Kidney recipients from Necker hospital
Other: No intervention
Kidney recipients from Saint-Louis hospital
Other: No intervention
Kidney recipients from Bichat hospital
Other: No intervention
Kidney recipients from Bretonneau hospital
Other: No intervention
Kidney recipients from Toulouse hospital
Other: No intervention
Kidney recipients from KU Leuven
Other: No intervention
Kidney recipients from Liege hospital
Other: No intervention
Kidney recipients from Leiden University Medical Center
Other: No intervention
Kidney recipients from Hospital of the University of Pennsylvania
Other: No intervention
Kidney recipients from Mayo Clinic
Other: No intervention
Kidney recipients data from real-world UCSF database
Other: No intervention
Kidney recipients data from real-world AP-HP database
Other: No intervention
No intervention
Patient death
Patient death
Time frame: Up to 10 years after kidney transplantation
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2004 to primary completion in Jun 2024, 245 months.
Of 85 non-industry observational studies under Death, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 245. This study's 245 months is above that.
Counting every sponsor, half of 88 studies reached it within 69 months; a quarter within 23 and three quarters within 245.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paris Translational Research Center for Organ Transplantation